Our latest news & events

Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes

TreeFrog Presents Data From Their Parkinson’s Cell Therapy Program At The American Academy Of Neurology Annual Meeting

TreeFrog’s Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

TreeFrog Therapeutics reinforces Executive Committee with three new members.

GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells.

The whole team wishes you a Merry Christmas & Happy New Year !

The machine will be transferred in 2023 to a contract development and manufacturing organization (CDMO) to produce TreeFrog’s cell therapy candidate for Parkinson’s disease, with the aim of a first-in-human trial in 2024. Over 2023, Invetech will deliver three additional GMP encapsulation devices to support TreeFrog’s in-house and partnered cell therapy programs in regenerative medicine and immuno-oncology.

We had the chance to interview Teisha Rowland, Ph.D., Principal Scientist at Umoja Biopharma during the ISSCR in San Francisco about the Umoja/TreeFrog partnership. Leading iPSC engineering at Umoja, she comes back on the vision of Umoja, its RACR™ technology and her interest in TreeFrog’s C-Stem™ platform for the development of iPSC-derived allogeneic products in immuno-oncology.

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

The whole team at TreeFrog Therapeutics wishes you a Happy New Year !

The whole team at TreeFrog Therapeutics wishes you a Happy New Year !

TreeFrog Therapeutics celebrated its 3rd anniversary on December 7th, 2021, announcing that the company increase its clean room capacity by two-fold in Pessac, to support its acceleration in cell therapy.

TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million (€70M).

The whole team at TreeFrog Therapeutics wishes you a Happy New Year !

treefrog therapeutics i-lab bpifrance